Dopamine Oxidation and Its Inhibition by (—)-Deprenyl in Man

  • Vivette Glover
  • J. D. Elsworth
  • M. Sandler
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 16)


Dopamine is predominantly oxidized by a (-)-deprenyl sensitive form of MAO in the human striatum, and (-)-deprenyl, acting at some suitably low selective inhibitory concentration may, therefore, be of benefit in Parkinson’s disease. 10-6M was the most effective (-)-deprenyl concentration in vitro for discriminating between the inhibition of MAO A and B. The correlation between the A/B ratio present in different human brain regions and the sensitivity of dopamine oxidation to 10-6M deprenyl was 0.84 (p < 0.001). This suggests that all dopamine oxidation can be accounted for by the joint contribution of MAO A and B and that it is unnecessary to postulate a special form of the enzyme which metabolizes dopamine. In the brain, the striatum has the highest proportion of MAO B, and in several cortical regions, relatively more dopamine is oxidized by MAO A. In other human tissues also the deprenyl sensitivity of dopamine oxidation correlated with the known A/B ratio, the placenta, lung and jejeunum having the lowest sensitivity and being the richest in MAO A. Km values for dopamine for MAO A and B are similar, 130 and 140 μM respectively, so that the proportion oxidized by the two forms should not vary with substrate concentration.


Monoamine Oxidase Phenyl Ethanolamine Dopamine Oxidation Human Striatum Human Brain Region 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barbeau, A., Sourkes, T.L., Murphy, G.F.: Les catécholamines dans la maladie de Parkinson. In: Monoamines et systéme nerveux central, pp. 247–262. Genéve: Georg. 1962.Google Scholar
  2. Birkmayer, W.: Experimentelle Befunde und neue Aspekte bei extrapyramidalen Erkrankungen. Wien. Z. Nervenheilk. 23, 128–139 (1966).PubMedGoogle Scholar
  3. Birkmayer, W., Hornykiewicz, O.: Der L-Dioxyphenylalanin(L-Dopa-)- Effekt beim Parkinson-Syndrom des Menschen. Arch. Psychiat. Nervenkr. 203, 560–574 (1962).PubMedCrossRefGoogle Scholar
  4. Birkmayer, W., Riederer, P., Youdim, M. B. H., Linauer, W.: The potentiation of the anti-kinetic effect after L-dopa treatment by an inhibitor of MAO B, deprenyl. J. Neural Transm. 36, 303–326 (1975).CrossRefGoogle Scholar
  5. Carlsson, A., T Lindqvist, M., Magnusson, T., Waldeck, B.:22 On the presence of 3-hydroxytyramine in brain. Science127, 471 (1958).PubMedCrossRefGoogle Scholar
  6. Donnelly, C. H.,Murphy, D. L.: Substrate- and inhibitor-related characteristics of human platelet MAO. Biochem. Pharmacol. 26, 853–858 (1977).PubMedCrossRefGoogle Scholar
  7. Edwards, D.J.:Phenylethanolamine is a specific substrate for type B monoamine oxidase. Life Sci. 23,1201–1208 (1978).PubMedCrossRefGoogle Scholar
  8. Egashira, T.: Studies on monoamine oxidase. XVIII. Enzymic properties of placental monoamine oxidase. Jap. J. Pharmacol. 26, 493–500 (1976).PubMedCrossRefGoogle Scholar
  9. Ehringer, H., Hornykiewicz,O.; Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wschr. 38, 1236–1239 (1960).PubMedCrossRefGoogle Scholar
  10. Elsworth, J. D., Glover, V., Reynolds, G. P., Sandler, M., Lees, A.J., Phuapradit, P., Shaw, K., Stern, G. M., Kumar, P.: Deprenyl administration in man: a selective MAO-B inhibitor without the “cheese effect”. Psychopharmacology 57, 33–38 (1978).PubMedCrossRefGoogle Scholar
  11. Elsworth, J. D., Glover, V., Sandler, M.: tele-Methylhistamine is a monoamine oxidase B substrate in man. (In preparation.)Google Scholar
  12. Fowler,J., Callingham, B. A., Mantle, T.J., Tipton, K. F.: Monoamine oxidase A and B: a useful concept? Biochem. Pharmacol. 27 97–101 (1978)CrossRefGoogle Scholar
  13. Glover V., Sandler, M., Owen, F., Riley, G.J.; Dopamine is a monoamine oxidase B substrate in man. Nature 265, 80–81 (1977).PubMedCrossRefGoogle Scholar
  14. Glover, V., Eisworth, J. D., Sandler, M.: Dopamine oxidation and its inhibition by (-)-deprenyl in human brain and tissues. In: Catecholamines: Basic and Clinical Frontiers (Proc. 4th Catecholamine Symposium, Asilomar, 1978), pp. 201–203. New York: Pergamon Press. 1979.Google Scholar
  15. Hough, L. B., Domino, E. F.: tele-Methylhistamine oxidation by type B monoamine oxidase. J. Pharmacol. exp. Ther. 208, 422–428 (1979).PubMedGoogle Scholar
  16. Johnston, J. P.: Some observations upon a new inhibitor of monoamine oxidase in brain tissue.Biochem. Pharmacol. 17, 1285–1297 (1968).PubMedCrossRefGoogle Scholar
  17. Knoll, J.. The possible mechanisms of action of (-)-deprenyl in Parkinson’s disease. J. Neural Transm. 43, 177–198 (1978).PubMedCrossRefGoogle Scholar
  18. Lees, A.J., Shaw, K. M., Kohout, L. J., Stern, G. M., Elsworth, J. D., Sandler, M., Youdim, M. B. H.: Deprenyl in Parkinson’s disease. Lancet ii, 791–795 (1977).CrossRefGoogle Scholar
  19. Lewinsohn, R., Glover, V., Sandler, M.: β-Phenylethylamine and benzylamine as substrates for human monoamine oxidase A: a source of some anomalies? Biochem. Pharmacol. (in press, 1979).Google Scholar
  20. Lowry,O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J.: Protein measurement with the Folin phenol reagent. J. biol. Chem. 193, 265–275 (1951).PubMedGoogle Scholar
  21. Murphy, D. L., Lipper, S., Slater, S., Shilling, D.: Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and Bin vivoin man. Psychopharmacology62, 129–132 (1979).PubMedCrossRefGoogle Scholar
  22. Owen, F., Gross, A. J., Loflhouse, R., Glover, V.: Distribution and inhibition characteristics of human brain monoamine oxidase. Biochem. Pharmacol. 28, 1077–1080 (1979).PubMedCrossRefGoogle Scholar
  23. Riederer, P., Youdim, M. B. H., Rausch, W. D., Birkmayer, W., Jellinger, K., Seemann, D.: On the mode of action of L-deprenyl in the human central nervous system. J. Neural Transm. 43, 217–226 (1978).PubMedCrossRefGoogle Scholar
  24. Schwartz, J. C.: Histaminergic mechanisms in brain. Ann. Rev. Pharmacol. Toxicol. 17, 325–339 (1977).CrossRefGoogle Scholar
  25. Waldmeier, P. C., Delini-Stula, A., Maitre, L.: Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn- Schmiedeberg’s Arch. Pharmacol. 292, 9–14 (1976).CrossRefGoogle Scholar
  26. Waldmeier, P. C., Feldtrauer, J.-J., Maitre, L.: Methylhistamine: evidence for selective deamination by MAO B in the rat brain in vivo. J. Neurochem. 29, 785–790 (1977).PubMedCrossRefGoogle Scholar
  27. White, H. L., Wu, J. C.: Multiple binding sites of human brain monoamine oxidase as indicated by substrate competition. J. Neurodiem. 25, 21–26 (1975).Google Scholar
  28. Yahr, M. D.: Overview of present day treatment of Parkinson’s disease. J. Neural Transm. 43, 227–238 (1978).PubMedCrossRefGoogle Scholar
  29. Youdim, M. B. H.: Multiple forms of monoamine oxidase and their properties. In: Monoamine Oxidases-New Vistas (Costa, E., Sandler, M.,eds.), pp. 67–77. New York: Raven Press. 1972.Google Scholar
  30. Youdim, M. B. H., Collins, G. G. S., Sandler, M.: Monoamine oxidase: multiple forms and selective inhibitors. Biochem. J. 121, 34P-36P (1971).PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • Vivette Glover
    • 1
  • J. D. Elsworth
    • 1
  • M. Sandler
    • 1
    • 2
  1. 1.Bernhard Baron Memorial Research Laboratories and Institute of Obstetrics and GynaecologyQueen Charlotte’s Maternity HospitalLondonUK
  2. 2.Bernhard Baron Memorial Research LaboratoriesQueen Charlotte’s Maternity HospitalLondonUK

Personalised recommendations